Arrhythmia

First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG

Retrieved on: 
Thursday, March 14, 2024
Health, FDA, Medical Devices, Health Technology, Clinical Trials, Cardiology, Biotechnology, Research, Diagnosis, FACC, Electrophysiology, Algorithm, Arrhythmia, Physician, Patient, Gold, Doctor of Philosophy, Deep learning, ECG, Medical device

HeartBeam AIMIGo leverages HeartBeam’s proprietary 3D vectorelectrocardiography (3D VECG) technology to capture signals in three projections (X, Y, Z) and synthesize a 12-lead ECG.

Key Points: 
  • HeartBeam AIMIGo leverages HeartBeam’s proprietary 3D vectorelectrocardiography (3D VECG) technology to capture signals in three projections (X, Y, Z) and synthesize a 12-lead ECG.
  • “We are thrilled to be part of this important study as AIMIGo represents a significant leap in cardiac monitoring technology.
  • All patients enrolled in the study will receive simultaneously recorded ECGs from a standard 12-lead ECG machine and the HeartBeam AIMIGo system.
  • The study will also examine the accuracy of physician diagnosis for various arrhythmias with the AIMIGo synthesized 12-lead ECG, compared to a standard 12-lead ECG.

Global Guidewires (Nitinol, Stainless Steel, Others) Market Report 2024: Analysis & Forecasts 2019-2022 and 2023-2029 - Minimally Invasive Techniques Expand, Boosting Guidewire Utilization - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
General Health, Health, Medical Supplies, Medical Devices, Disease, PVI, Friction, ERCP, Coronary artery disease, Conditional sentence, Bacteria, Epidemiology, Specialization, Risk, Investment, Infection, Patient safety, USD, Surgery, Non-communicable disease, Cardiovascular disease, Fungal infection, Obesity, Biotechnology, Peripheral artery disease, Porter's five forces analysis, Diabetes, Chlorhexidine, World Health Organization, Safety, Fatigue, Hypertension, Cardiology, Neurology, Urology, Prevalence, Death, PCI, Diagnosis, Arrhythmia, Temperature, Growth, Incidence, Anatomy, SWOT, Mortality, Stainless steel, WHO, Nickel titanium, Physician, Medical imaging

Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.

Key Points: 
  • Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.
  • As the prevalence of risk factors such as obesity, diabetes, and hypertension increase, so does the incidence of cardiovascular diseases.
  • Guidewires are essential tools in percutaneous coronary interventions (PCI), peripheral vascular interventions (PVI), and electrophysiology procedures, driving the demand for guidewires.
  • The increasing prevalence of chronic diseases worldwide drives the demand for guidewires by necessitating minimally invasive interventions for diagnosis and treatment.

Proem Introduces 'Touchless' Mental Health Care Workflow

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Depression, Organization, Letter, Arrhythmia, Patient, Preface, Triage, Anxiety, Workflow, Pediatrics, Workload, EHR, EKG, Obstetrics, Health, ECG, Nursing

ATLANTA, April 3, 2024 /PRNewswire-PRWeb/ -- Proem Behavioral Health, developer of evidence-based mental health assessment and measurement technology, is pleased to announce a new software version that provides a touchless workflow experience for clinicians and staff. The new release makes it easy for health care providers – including those in primary care, pediatrics, obstetrics, federally qualified health centers, and behavioral health and addiction clinics – to screen, assess, diagnose and track patients who suffer from mental illness.

Key Points: 
  • ATLANTA, April 3, 2024 /PRNewswire-PRWeb/ -- Proem Behavioral Health, developer of evidence-based mental health assessment and measurement technology, is pleased to announce a new software version that provides a touchless workflow experience for clinicians and staff.
  • The new release makes it easy for health care providers – including those in primary care, pediatrics, obstetrics, federally qualified health centers, and behavioral health and addiction clinics – to screen, assess, diagnose and track patients who suffer from mental illness.
  • "As the mental health crisis in America grows, patients are increasingly seeking behavioral health services from their primary care and other physical medicine providers due to convenience, comfort and reduced stigma," explains Proem CEO John Letter.
  • "Our latest platform update reflects our mission to simplify the mental health care journey for providers and patients.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
Tuesday, March 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
Tuesday, March 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Adagio Medical Announces CE Mark approval of VT Cryoablation System, Plans for Immediate Commercialization in Select European Centers

Retrieved on: 
Monday, March 25, 2024
CE marking, Temperature, Electrophysiology, Atrial fibrillation, Patient, Journal, Ventricular tachycardia, Science, McGill University Health Centre, MD, CCB, Tachycardia, Catheter ablation, Division, Arrhythmia, Catheter, Adagio, Medical device

The system consists of the upgraded cryoablation console, also capable of supporting atrial ablation procedures using commercially available iCLAS™ catheters, and the vCLAS™ ventricular cryoablation catheter ("vCLAS").

Key Points: 
  • The system consists of the upgraded cryoablation console, also capable of supporting atrial ablation procedures using commercially available iCLAS™ catheters, and the vCLAS™ ventricular cryoablation catheter ("vCLAS").
  • The system will be featured at the upcoming conference of the European Heart Rhythm Association ("EHRA") in Berlin on April 7-9, 2024 and will become immediately available for clinical use in select European centers.
  • Unlike conventional radiofrequency ("RF") catheters commonly used for both ventricular and atrial procedures, the 9Fr, bi-directional deflectable vCLAS catheter was designed specifically to address the challenges of VT ablations.
  • CE Mark approval for the vCLAS catheter has been granted based on the results of the Cryocure-VT trial, which enrolled patients with monomorphic VT of both ischemic and non-ischemic origin at nine European and Canadian centers.

Advisory - Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches

Retrieved on: 
Wednesday, March 20, 2024
Palpitations, Varenicline, Chest pain, Xerostomia, Dizziness, Weakness, Caregiver, Nervous, Indigestion, Sleep, Risk, Headache, NPN, Health, Nicotine, Angina, Internet, Stroke, Constipation, Smoke, Death, Heartburn, Health Canada, Arrhythmia, Nausea, Medicine, Nursing, Safety, Fatigue, Vomiting, Blurred vision, Allergy, Parent, Chronic pain, Advertising, Tobacco

Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.

Key Points: 
  • Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.
  • Use authorized nicotine pouches only as directed:
    To date, Health Canada has authorized only one nicotine pouch , containing 4 mg of nicotine per dose.
  • Nicotine replacement therapies, including nicotine pouches, are not authorized for recreational use or for use by nonsmokers and people under 18 years old.
  • There are no authorized nicotine pouches in Canada that contain more than 4 mg of nicotine per dose.

Methodist Le Bonheur Healthcare first in Tennessee to offer "paradigm-shifting" technology for AFib patients

Retrieved on: 
Thursday, March 14, 2024
MLH, Le Bonheur Children's Hospital, Heat, Atrial fibrillation, Anesthesia, Patient, Methodist University Hospital, PFA, Medtronic, Freezing, Arrhythmia, Ventricular fibrillation, Methodism, Cardiac electrophysiology, Hospital

MEMPHIS, Tenn. , March 14, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare is proud to announce it is the first healthcare system in Tennessee to offer the Medtronic PulseSelect™ Pulsed Field Ablation (PFA) technology to patients suffering from atrial fibrillation (AF).

Key Points: 
  • MEMPHIS, Tenn. , March 14, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare is proud to announce it is the first healthcare system in Tennessee to offer the Medtronic PulseSelect™ Pulsed Field Ablation (PFA) technology to patients suffering from atrial fibrillation (AF).
  • "Pulsed Field Ablation is a paradigm-shifting technology," said Dr. Yehoshua Levine, division chief of cardiac electrophysiology at Methodist Le Bonheur Healthcare who performed the first PFA at Methodist University Hospital.
  • "PFA allows us to deliver timely treatment to more patients when they need help the most," said Dr. James Litzow, cardiac electrophysiologist with Methodist Le Bonheur Germantown Hospital.
  • Across the MLH system , the cardiovascular team at Methodist University Hospital conducted the first PFA for the healthcare system on March 11 with Methodist Le Bonheur Germantown Hospital's cardiovascular team conducting its first PFA on March 12.

IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Retrieved on: 
Monday, March 11, 2024
Zio, Court, Letter, Action Replay, FDA, Physician, News, Advertising, Complaint, District court, IRTC, Arrhythmia, Patient, Security (finance)

If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.

Key Points: 
  • If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 8, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Thursday, March 7, 2024
Diuretic, Ultrafiltration, Hospital, Section, Artificial intelligence, Randomized controlled trial, Mount Sinai Health System, Quality of life, Acute decompensated heart failure, Hierarchy, Aquapheresis, Valvular heart disease, Risk, Heart failure, Arrhythmia, AUF, ALD, History, Yale School of Medicine, Patient, HF, Machine learning, Cerebrovascular disease, THT, Mortality, Roflumilast, Pharmaceutical industry

MINNEAPOLIS, March 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced results from two new clinical data analyses from the AVOID-HF trial, which demonstrate the benefits of its Aquadex System in reducing heart failure readmissions at 30 days. Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.

Key Points: 
  • Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
  • Key findings demonstrating the benefits of AUF include:
    Fewer heart failure events and heart failure hospitalizations: AUF patients had significantly fewer heart failure events within 30 days compared to ALD (90% vs 77.3% p=0.0138) and fewer heart failure hospitalizations for the AUF patients compared to the ALD patients (90.0% vs. 79.2% p=0.0321) within 30 days.
  • Key findings from the analysis include:
    Top predictors for 90-day heart failure events: Using ML, the study identified the top 10 predictors for 90-day heart failure events.
  • Strong results for super-responders: 90% of patients categorized as super-responders to AUF therapy within this model did not experience any 90-day heart failure events.